| This week's sponsor is Catalent. | | | [Fact Sheet] Biologics Device Assembly & Packaging
Catalent’s biologics packaging operations in the US and Belgium offer state-of-the-art, high-speed, automated equipment, as well as configurable packaging solutions to support both clinical and commercial supply. Learn more about Catalent’s device assembly and packaging capabilities for biologics. |
| Welcome to FierceLifeSci Weekly Digest, your roundup of the biggest and most popular stories from each of our publications. CAR-T has seen a host of successes in blood cancers, but translating that into solid tumors has proven to be much harder. However, early data from two separate small trials may be offering some hope in that direction. They were presented at the annual meeting of the American Association for Cancer Research, where the small California biotech Apexigen has been turning heads with a combo therapy of its CD40-activating antibody plus Bristol-Myers Squibb’s Opdivo and chemo. The treatment shrunk advanced pancreatic tumors in 20 of 24 patients in a phase 1b study, and the companies are already planning on moving to phase 2. | |
|
Featured Story | | | Sunday, March 31, 2019 CAR-T has seen a host of successes in blood cancers, but translating that into solid tumors has proven much more difficult. Now, early data out of the AACR cancer conference (and all the caveats that brings) may be offering some hope for that direction. |
|
|
Top Stories Of The Week Monday, April 1, 2019 California biotech Apexigen said during the annual American Association for Cancer Research meeting that a combination of its CD40-activating antibody with Bristol-Myers Squibb’s PD-1 inhibitor Opdivo and chemotherapy shrunk tumors in 20 out of 24 patients with pancreatic cancer. Tuesday, April 2, 2019 AbbVie's Humira is likely the most-watched drug in biopharma right now, and a new investigative report shows how the company moved to keep business upon the introduction of biosimilars in the Netherlands. Friday, March 29, 2019 Johnson & Johnson Vision has begun the U.S. launch of its adaptive contact lenses that darken to match changing light levels, employing the same technology seen in Transitions eyeglass lenses. Monday, April 1, 2019 Kickbacks, $10,000 dinners and Hooters. Details that sound pulled from an episode of "Billions" are key accusations in a federal lawsuit against Swiss drugmaker Novartis that could face a jury trial after a district judge's order Monday. Friday, March 29, 2019 AstraZeneca is willing to bet nearly $7 billion on an antibody drug conjugate out of Japanese pharma Daiichi’s pipeline as it looks beyond checkpoint inhibitor Imfinzi. Wednesday, April 3, 2019 The #FierceMadness final game is set—and it’ll be GlaxoSmithKline's Trelegy taking on Boehringer Ingelheim's Ofev for the 2019 title. Tuesday, April 2, 2019 Novartis has big plans in gene therapies, and its biotech AveXis is building out a significant manufacturing network to help the Swiss drugmaker realize them. The drugmaker says it has bought a former AstraZeneca plant in Colorado, adding to three production sites it already has. Friday, March 29, 2019 Novo Nordisk reached an agreement that will hold generic competition to its newer diabetes drugs for another five years. With that in the bag, it can now focus on next-generation products and so is investing nearly $100 million in its massive site in Denmark to make them. Monday, April 1, 2019 After a number of pacts and buyouts over the past few years, Charles River Labs is cutting staff at one of its California sites. | This week's sponsor is FierceBiotech. | | | |
Resources Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. |
